# Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

> **NCT00601978** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** carbidopa/levodopa
- **DRUG:** Carbidopa/Levodopa/Entacapone

## Key facts

- **NCT ID:** NCT00601978
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-08
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision brand strategy; no patients enrolled
- **Last updated:** 2012-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601978, "Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00601978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*